Top news of the week from Specialty Pharmacy Times.
Cladribine (Mavenclad, EMD Serono) is the first oral multiple sclerosis drug to demonstrate 2 years of proven efficacy with a maximum of 20 days of treatment. Read more.
Gilteritinib (Xospata) was superior to standard chemotherapy in improving overall survival in patients with acute myeloid leukemia. Read more.
Immune Globulin Intravenous, Human — slra 10% Liquid (Asceniv) is indicated for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents. Read more.
Although lung cancer screenings are covered at no cost by most insurers, state Medicaid programs are not required to offer coverage for this service. Read more.
Specialty pharmacy can benefit from having definitive a center of excellence model that caters to respective therapies and disease states. Read more.